Product Description
Tapotoclax is an inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/118910268)
Mechanisms of Action: MCL-1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Germany, Japan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Leukemia, Plasma Cell|Multiple Myeloma|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2080224749 | P1 |
Recruiting |
Acute Myeloid Leukemia|Multiple Myeloma |
2025-10-21 |
|
| NCT02675452 | P1 |
Completed |
Acute Myeloid Leukemia|Multiple Myeloma|Leukemia, Plasma Cell |
2024-05-27 |
|
| NCT05209152 | P1 |
Completed |
Chronic Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Preleukemia|Acute Monocytic Leukemia|Myelodysplastic Syndrome |
2023-12-19 |
48% |